Trypanosoma brucei CTP synthetase: A target for the treatment of African sleeping sickness
AUTOR(ES)
Hofer, Anders
FONTE
The National Academy of Sciences
RESUMO
The drugs in clinical use against African sleeping sickness are toxic, costly, or inefficient. We show that Trypanosoma brucei, which causes this disease, has very low levels of CTP, which are due to a limited capacity for de novo synthesis and the lack of salvage pathways. The CTP synthetase inhibitors 6-diazo-5-oxo-l-norleucine (DON) and α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin) reduced the parasite CTP levels even further and inhibited trypanosome proliferation in vitro and in T. brucei-infected mice. In mammalian cells, DON mainly inhibits de novo purine biosynthesis, a pathway lacking in trypanosomes. We could rescue DON-treated human and mouse fibroblasts by the addition of the purine base hypoxanthine to the growth medium. For treatment of sleeping sickness, we propose the use of CTP synthetase inhibitors alone or in combination with appropriate nucleosides or bases.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=33482Documentos Relacionados
- Galactose metabolism is essential for the African sleeping sickness parasite Trypanosoma brucei
- Immunopathology of experimental African sleeping sickness: detection of cytokine mRNA in the brains of Trypanosoma brucei brucei-infected mice.
- Glycosylphosphatidylinositol biosynthesis validated as a drug target for African sleeping sickness
- African sleeping sickness
- Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness
